Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target was raised to $65.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors, primarily the promising results from Dianthus Therapeutics’ Phase II MaGic study. The study evaluated claseprubart in patients with AChR+ generalized myasthenia gravis and demonstrated rapid and significant symptom improvement with a favorable safety profile. The 300mg Q2W treatment arm achieved statistical significance across all efficacy measures compared to placebo, which strengthens the case for claseprubart as a leading complement inhibitor for gMG treatment.
Additionally, the absence of new autoimmune diseases in clinical trials and real-world use enhances confidence in the drug’s safety. The self-administered subcutaneous route of administration and potential for quarterly dosing further add to its appeal. These factors, along with a large commercial opportunity and an updated 12-month price target of $65 per share, underpin Katkhuda’s positive outlook on Dianthus Therapeutics.